Please assess the completion status of the following clinical trial:

Trial Title: Gated Intensity Modulated Radiation Therapy and Concurrent Chemotherapy for Inoperable NSCLC

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with histologically-proven, by biopsy or cytology, unresectable lung cancer of the following histologic types: squamous cell carcinoma, adenocarcinoma, large cell carcinoma, non-small cell carcinoma, not otherwise specified.~* Patient with AJCC Stage IIIA-IIIB, if all detectable tumor can be encompassed by radiation therapy fields, including both the primary tumor and the involved regional lymph nodes.~* 18-fluoro-2-deoxyglucose positron emission tomography required for staging and image fusion for treatment planning.~* Atelectasis, if present, must be less than one lung.~* Patients must have granulocytes \>1500/µl; platelets \>100,000/µl; bilirubin \< 1.5 mg/dl; AST(SGOT) \< 2 ULN; serum creatinine \< 2.0 mg/dl.~* Zubrod Score 0-1.~* FEV1 must be \>1.0 L.~* Patients must sign a study-specific informed consent form prior to study entry~* Patients must have measurable disease on the planning CT.~* Patient must have a completed the IMRT plan and the attending physician must have reviewed and approved the dose volume histograms as follows (based on treatment planning to the Phase 4 dose level): total lung V20 \< 30%, mean esophageal dose \< 34 Gy, the esophageal V55 \< 30%, the heart V40 \< 50%.~* No prior or concurrent malignancy except non-melanomatous skin cancer unless disease-free for one year or more; no prior lung cancer within last two years.~* No prior RT to thorax.~* No previous chemotherapy or previous biologic response modifiers for current lung cancer or within the past five (5) years.~* No distant metastases or supraclavicular lymph node involvement or significant atelectasis.~* No clinically significant pleural effusions, pericardial effusions or superior vena cava syndrome.~Exclusion Criteria:~* Undifferentiated small cell (oat cell or high grade neuroendocrine) carcinoma, any stage.~* Stage I, II or IV NSCLC.~* Complete tumor resection, recurrent disease, or those patients eligible for definitive surgery.~* Concurrent malignancy except non-melanomatous skin cancer or prior cancer unless disease-free for one year or more.~* Prior radiation therapy to the thorax.~* Previous chemotherapy or previous biologic response modifiers for current lung cancer or within the past five (5) years.~* Distant metastases or supraclavicular lymph node involvement, or atelectasis of an entire lung.~* Patients who have not had the pre-treatment evaluations in Section 4.0 or evaluations performed \> 8 weeks prior to study entry.~* Patients with clinically significant pleural effusions, pericardial effusions or superior vena cava syndrome.~* Prior lung cancer within the last two years.~* Patients who have significant atelectasis and in whom the CT definition of the gross tumor volume(GTV) is difficult to determine.~* Pregnant or lactating females. It is not known what effects this treatment may have on the developing fetus.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A (Type: EXPERIMENTAL): Fractionated Radiation Therapy followed by Carboplatin and Taxol

Based on this trial design, predict the completion outcome and termination type (if applicable).